Mutant BRAF Melanomas—Dependence and Resistance

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 • 4,320 citations

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 • 3,500 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

2010 • 1,767 citations

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 • 1,729 citations

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

2010 • 1,552 citations

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

2010 • 1,438 citations

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 • 1,404 citations

BRAF mutation predicts sensitivity to MEK inhibition

2005 • 1,312 citations

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

2008 • 1,306 citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

2010 • 1,218 citations

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

2008 • 500 citations

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

2010 • 444 citations

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

2010 • 390 citations

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

2010 • 340 citations

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

2010 • 303 citations

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

2010 • 278 citations

Inhibitor hijacking of Akt activation

2009 • 276 citations

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells

2010 • 225 citations

Chapter 1 Ras Signaling and Therapies

2009 • 195 citations

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression

2009 • 168 citations

Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies

2010 • 156 citations

Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape

2008 • 148 citations

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

2008 • 131 citations

PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity

2009 • 130 citations

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

2010 • 121 citations